Aurinia Pharmaceuticals (NASDAQ: AUPH) net income
Aurinia Pharmaceuticals reported a net profit of $287.2m for fiscal 2025, 4,893.1% more than in fiscal 2024 ($5.8m). Its net margin was 101.5%. Earnings per share were $2.14.
Fiscal 2025 is the highest of the 7 fiscal years on record for Aurinia Pharmaceuticals. It reported a loss in 5 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $287.2m | +4,893.1% | 101.5% | $2.14 |
| 2024 | $5.8m | — | 2.4% | $0.04 |
| 2023 | −$78.0m | — | −44.5% | −$0.54 |
| 2022 | −$108.2m | — | −80.7% | −$0.76 |
| 2021 | −$181.0m | — | −396.8% | −$1.40 |
| 2020 | −$102.7m | — | −204.9% | −$0.87 |
| 2019 | −$88.4m | — | −27,794.0% | −$0.95 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Aurinia Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Aurinia Pharmaceuticals ranks 75th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Aurinia Pharmaceuticals, 101.5%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 73rd | Halozyme Therapeutics | $316.9m | 22.7% |
| 74th | Alnylam Pharmaceuticals | $313.7m | 8.4% |
| 75th | Aurinia Pharmaceuticals | $287.2m | 101.5% |
| 76th | BeOne Medicines | $286.9m | 5.4% |
| 77th | Innoviva | $271.2m | 65.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Aurinia Pharmaceuticals
- How much did Aurinia Pharmaceuticals earn in fiscal 2025?
- Aurinia Pharmaceuticals reported a net profit of $287.2m for fiscal 2025. In fiscal 2024 it reported a net profit of $5.8m.
- What are the earnings per share of Aurinia Pharmaceuticals?
- They were $2.14 in fiscal 2025, compared with $0.04 in fiscal 2024.
- What is the net margin of Aurinia Pharmaceuticals?
- In fiscal 2025 its net profit was 101.5% of its revenue.
- What was the most profitable year for Aurinia Pharmaceuticals?
- Of its last 7 fiscal years, fiscal 2025, with $287.2m.
- Where does Aurinia Pharmaceuticals rank in its sector by net income?
- It ranks 75th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Aurinia Pharmaceuticals come from?
- From the annual report (Form 10-K) that Aurinia Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Aurinia Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Aurinia Pharmaceuticals: the Aurinia Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.